Tag: pharma

This week: 72nd World Health Assembly

From May 20-28, the 72nd session of the World Health Assembly (WHA) will take place in Geneva, Switzerland. Each year, senior health officials from the World Health Organization’s (WHO) Member States gather there to discuss the WHO’s progress, new goals and global health agenda and challenges. Wemos will be present as well as a civil society organization and attend sessions on Financing for Health, the Global Action Plan for Healthy Lives and Well-being and Access to Medicines.

Continue reading

Overpriced drugs developed with tax money

Research shows major Dutch public investments in drug development

 

Overpriced, a report published today jointly by The Centre for Research on Multinational Corporation (SOMO) and Wemos, examines the extent of Dutch public funding of drug development, through donations, loans and/or investments. This funding occurs both directly by financing development of new medicines, and indirectly through investments made into biotech companies, but channelled through universities, public research bodies, and national and regional investment funds. The report reveals, however, that because no conditions are set on these investments, the Government loses its chance to curb subsequent high drug prices.

Continue reading

EU Medicines Manifesto: put the health of European citizens first

There is increasing pressure on access to affordable, innovative medicines for many European citizens. Change is urgently needed. This key message emerges from the joint manifesto by several members of the Medicines Network Netherlands (Medicijnen Netwerk Nederland), of which Wemos is a member. The publication of the manifesto anticipates the European Parliament elections to be held on 23 May 2019.

Continue reading

‘Minister Bruins: reform the granting of supplementary protection certificates for new medicines’

The granting of supplementary protection certificates for new medicines must be reformed. This is our message in a letter to Minister Bruins (Dutch Ministry of Health, Welfare and Sport), signed by Wemos, Aidsfonds, Commons Network, the Dutch Pharmaceutical Accountability Foundation, Health Action International (HAI) and the Centre for Research on Multinational Corporations (SOMO).

Continue reading